Tamio Okimoto

Dr. Tamio Okimoto

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 March 2019 in Internal Medicine
Verified
Journal Article
Open access
PDF file
TOTamio Okimoto
Tamio Okimoto
YTYukari Tsubata
Yukari Tsubata
THTakamasa Hotta
Takamasa Hotta
MHMegumi Hamaguchi
Megumi Hamaguchi
MNMika Nakao
Mika Nakao
TITakeshi Isobe
Takeshi Isobe
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

29 January 2018 in Respirology Case Reports
Verified
Journal Article
Open access
PDF file
TOTamio Okimoto
Tamio Okimoto
YTYukari Tsubata
Yukari Tsubata
MHMegumi Hamaguchi
Megumi Hamaguchi
ASAkihisa Sutani
Akihisa Sutani
SHShunichi Hamaguchi
Shunichi Hamaguchi
TITakeshi Isobe
Takeshi Isobe
Although rare, pleuroparenchymal fibroelastosis (PPFE) is a serious late‐onset complication of haematopoietic stem cell transplantation (HSCT). It remains unclear whether graft‐versus‐host disease (GVHD) is involved in the development of PPFE. We report the case of a patient with PPFE after HSCT. The patient experienced pneumothorax repeatedly despite surgical treatment. A surgical specimen demonstrated PPFE findings, without evidence of GVHD. In this case, development of PPFE was not associated with GVHD, and immunosuppressive therapy did not improve pulmonary function. Surgical biopsy is recommended for precise treatment and elucidation of pathogenesis in each suspected PPFE patient.

1 August 2012
Verified
Journal Article
Closed access
YTYukari Tsubata
Yukari Tsubata
ASAkihisa Sutani
Akihisa Sutani
TOTamio Okimoto
Tamio Okimoto
MMMotoki Matsuura
Motoki Matsuura
IMIsao Murakami
Isao Murakami
TITakeshi Isobe
Takeshi Isobe

7 August 2024 in Cancers
Verified
Journal Article
Open access
PDF file
HKHitoshi Kotani
Hitoshi Kotani
WHWei Han
Wei Han
YIYuichi Iida
Yuichi Iida
RTRyosuke Tanino
Ryosuke Tanino
KKKazuaki Katakawa
Kazuaki Katakawa
MHMAMORU HARADA
MAMORU HARADA
Background: Tyrosine kinase inhibitors (TKIs) inhibit receptor-mediated signals in cells. Axitinib is a TKI with high specificity for vascular endothelial growth factor receptors (VEGFRs). Aim: We determined whether axitinib could induce senescence in human cancer cells and be lysed by the senolytic drug ABT-263. Methods: Human lung and breast adenocarcinoma cell lines were used. These cells were cultured with axitinib or a multi-target TKI lenvatinib. The expression of β-galactosidase, VEGFRs, Ki-67, reactive oxygen species (ROS) of cancer cells, and their BrdU uptake were evaluated by flow cytometry. The mRNA expression of p21 and IL-8 was examined by quantitative PCR. The effects of TKIs on phosphorylation of Akt and Erk1/2, as downstream molecules of VEGFR signaling, were examined by immunoblot. The in vivo anti-cancer effect was examined using a xenograft mice model. Results: Axitinib, but not lenvatinib, induced cellular senescence (increased cell size and enhanced expression of β-galactosidase) in all adenocarcinoma cell lines. Axitinib-induced senescence was unrelated to the expression of VEGFRs on cancer cells. ROS were involved in axitinib-induced senescence. Axitinib-induced senescent lung adenocarcinoma A549 cells were drastically lysed by ABT-263. In A549-xenografted mice, combination therapy with axitinib and ABT-263 significantly suppressed tumor growth with the induction of apoptotic cancer cells.

9 April 2023 in Respirology Case Reports
Verified
Journal Article
Open access
KNKazuhisa Nakashima
Kazuhisa Nakashima
YMYuki Mitarai
Yuki Mitarai
STSeiko Tanaka
Seiko Tanaka
MNMika Nakao
Mika Nakao
TOTakae Okuno
Takae Okuno
TITakeshi Isobe
Takeshi Isobe
An 83‐year‐old woman with RET fusion‐positive advanced lung adenocarcinoma was administered selpercatinib 320 mg/day. Despite the shrinking of the tumour, fever, fatigue, and anorexia developed on day 17. Selpercatinib administration was interrupted. On day 21, elevated blood aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were observed. On day 28, AST and ALT levels increased to demonstrate Grade 4 in CTCAE Ver.5. The patient received a glycyrrhizin‐compounding agent and steroid treatment, and AST and ALT levels gradually decreased. On day 63, selpercatinib 160 mg/day was restarted after improvement of the hepatic disorder. Since then, selpercatinib was continued without any severe adverse events. Selpercatinib is a reasonable treatment option for RET fusion‐positive advanced non‐small cell lung cancer even in older patients. However, old age may be a risk factor for adverse events including hepatic disorders. For safe treatment in such patients, careful follow‐up is required.